Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development |
[07-February-2019] |
HOUSTON, Feb. 7, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development. In this role, she will be responsible for clinical development strategy, clinical study design, and medical oversight of the Company's therapeutic product candidates. Dr. Koneru joins Marker Therapeutics from Eli Lilly and Company, where she served most recently as Associate Vice President of Immuno-Oncology.
"We are pleased to welcome an executive with Mythili's extensive experience and expertise in the immunotherapy and cell therapy field," said Peter L. Hoang, President and Chief Executive Officer. "Her impressive background in translational medicine and immuno-oncology, her proven leadership in clinical trial design and drug development, and her extensive patient care experience, will be invaluable in advancing our pipeline of next-generation T cell therapy candidates. We look forward to her many contributions to our future success." In her previous role as Associate Vice President of Immuno-Oncology at Eli Lilly and Company, Dr. Koneru designed early-stage clinical trials for hematologic and solid tumor malignancies and was instrumental in developing clinical trial protocols, serving as medical lead for trial conduct. She has also served as Senior Medical Director of Early Phase Clinical Development at Eli Lilly before she was promoted to her most recent position. Prior to Eli Lilly, Dr. Koneru was an Oncology Fellow in the laboratory of Dr. Renier Brentjens at Memorial Sloan-Kettering Cancer Center, where she developed adoptive T cell therapies in both leukemia and solid tumor malignancies in early phase clinical trials. Dr. Koneru earned a B.A. in Cellular and Molecular Biology from the University of Chicago, a Ph.D. in Biomedical Research: Tumor Immunology from New York University, and an M.D. from the Robert Wood Johnson Medical School. About Marker Therapeutics, Inc. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStartâ„¢ that can enhance the ability of the immune system to recognize and destroy diseased cells. For additional information, please call toll free at (904) 862-6490 or visit: markertherapeutics.com To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/ Follow us on Twitter @MRKRTherapeutic, or follow us on Facebook. Forward-Looking Statement Disclaimer
View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-appoints-mythili-koneru-md-phd-as-senior-vice-president-clinical-development-300791223.html SOURCE Marker Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:MRKR |
© 2019 PR Newswire. All Rights Reserved.